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Abstract
Low-grade inflammation (LGI) is a central phenomenon in the genesis of obesity and insulin-resistance characterized by IL-6
in human serum. Whereas this LGI was initially thought to be mainly attributed to macrophage activation, it is now known
that pre-adipocytes and adipocytes secrete several adipokines including IL-6 and participate to LGI and associated
pathologies. In macrophages, HMGB1 is a nuclear yet secreted protein and acts as a cytokine to drive the production of
inflammatory molecules through RAGE and TLR2/4. In this paper we tested the secretion of HMGB1 and the auto- and
paracrine contribution to fat inflammation using the human preadipocyte cell line SW872 as a model. We showed that 1)
human SW872 secreted actively HMGB1, 2) IL-6 production was positively linked to high levels of secreted HMGB1, 3)
recombinant HMGB1 boosted IL-6 expression and this effect was mediated by the receptor RAGE and did not involve TLR2
or TLR4. These results suggest that HMGB1 is a major adipokine contributing to LGI implementation and maintenance, and
can be considered as a target to develop news therapeutics in LGI associated pathologies such as obesity and type II
diabetes.
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hold fellowships from Regional Council of La Réunion. VGTH is a fellow from the French Ministry (contrat doctoral). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wildriss.viranaicken@univ-reunion.fr
. These authors contributed equally to this work.
Introduction
HMGB1 is a non-histone nuclear protein which is a highly
conserved, ubiquitous and is comprised of 215 amino acids that
are organized in two globular DNA-binding domains, box A and
box B, and with an acidic C-terminal tail [1,2]. HMGB1 can bind
DNA, helps chromosome architecture organization and regulates
transcription of genes. Outside the cell, HMGB1 can function as a
chemokine or an alarmin to activate the immune system and
mediate a wide range of physiological and pathological responses
including autoimmunity, cancer, trauma, hemorrhagic shock and
ischemia-reperfusion injury [3]. HMGB1 can be released in two
conditions: an active secretion by immune cells or a passive
secretion initiated by cellular damage like cell death [4]. The
shuttling of HMGB1 between the nucleus and the cytoplasm is
dependent of post-translational modifications that influence its
traffic [5].
Once in the extracellular space, HMGB1 interacts with the
receptor for advanced glycation end products (RAGE) and/or
members of the Toll-like family of receptors (TLRs) including
TLR2 and TLR4. Activation of these receptors results in the
activation of NF-kB, which influences the production of pro-
inflammatory cytokines [3]. Moreover, activation of NF-kB
induces the expression of HMGB1 receptors, and increases
secretion of HMGB1 inducing a positive feedback loop of
HMGB1-mediated inflammatory response [6].
The role of HMGB1 on macrophages is clearly described and
stimulation of macrophages with HMGB1 induces a production of
pro-inflammatory cytokines [7] which can lead to an increase of
adipose tissue inflammation and insulin resistance.
Obese adipose tissue is characterized by low grade inflamma-
tion (LGI) [8] that is characterized by robust secretion of pro-
inflammatory cytokines including IL-6 and active recruitment of
leukocytes, mainly macrophages in the affected tissues [9]. These
cytokines are known to be involved in insulin desensitization
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phenomenon which could contribute to obesity and type 2
diabetes [10].
However long before the onset of obesity and macrophages
infiltration, adipose tissue is able to implement and maintain LGI.
Indeed it has been recognized that adipocytes also demonstrate
significant inflammatory properties like IL-6 or TNFa production
[11,12]. IL-6 expression in adipocytes is governed by an autocrine
positive feedback loop and is upregulated by insulin. It has been
shown that IL-6 upregulation in adipocytes leads to insulin
resistance by activating SOCS3 in target cells like hepatocytes
[13,14,15].
Moreover, pre-adipocytes contribute significantly to inflamma-
tion of the adipose tissue in obesity [16,17,18]. It has been
demonstrated that pre-adipocytes can function as macrophage-like
cells and may play a direct role in the inflammation response and
obesity [19,20]. Expression profile of pro-inflammatory factors
differs between adipocytes and pre-adipocytes and they may play
different, but yet, complementary roles in inflammation of adipose
tissues [18]. In addition, adipocytes can control the proliferation of
pre-adipocytes [21] which accumulate thereby contributing
further to inflammation of the adipose tissue. Pre-adipocytes and
adipocytes produced mostly IL-8 and IL-6 pro-inflammatory
cytokines and less TNF-a [22] which is mostly produced by
macrophages. All of these observations show a central role of pre-
adipocytes and adipocytes in the inflammatory status and LGI of
adipose tissue mainly mediated by IL-6 secretion and its
implication in insulin resistance.
A number of studies have demonstrated an autocrine and
paracrine effect of HMGB1 on macrophages which can potent
LGI. However, it is not known whether preadipocytes and
adipocytes may secrete and respond to HMGB1. There is
currently no published report regarding HMGB1 expression and
functions in fat cells and possible links to LGI in obesity. In this
study we investigated the implication of HMGB1 in the regulation
of inflammation in preadipocytes using the human preadipocyte
cell line SW872 as a model. We showed that HMGB1 is released
actively by SW872 and that extracellular HMGB1 contributes to
IL-6 secretion through RAGE. These results suggest that HMGB1
Table 1. List of primers used in this study for RT-PCR on SW872 RNA.
Gene Genre Genbank Primers Sequences Amplicon (pb)
GAPDH human NM_002046.4 Forward 5’- GCCTTCTCCATGGTGGTGAA -3’ 151
Reverse 5’- GCACCGTCAAGGCTGAGAGAAC -3’
TLR2 human NM_003264.3 Forward 5’- GCCTCTCCAAGGAAGAATCC -3’ 329
Reverse 5’- AGAAGAAAGGGGCTTGAACC -3’
TLR4 human NM_138557.2 Forward 5’- ACCCTTTAGCCCAGAACTGC -3’ 227
Reverse 5’- GTCTCACGCAGGAGAGCCAG -3’
RAGE human NM_001136.4 Forward 5’- GCCAGAAGGTGGAGCAGTAG -3’ 357
Reverse 5’- AAGATGACCCCAATGAGCAG -3’
HMGB1 human NM_002128.4 Forward 5’- CCAAAGGGGAGACAAAAAAAG -3’ 193
Reverse 5’- TCATAAGGCTGCTTGTCATCT -3’
IL-6 human NM_000600.3 Forward 5’- ACCCCCAGGAGAAGATTCCA -3’ 162
Reverse 5’- GCCTCTTTGCTGCTTTCACA -3’
MCP1 human NM_002982.3 Forward 5’- CAATAGGAAGATCTCAGTGC -3’ 188
Reverse 5’- GTGTTCAAGTCTTCGGAGTT -3’
TNF-a human NM_000594.3 Forward 5’- TCCAGGCGGTGCTTGTTCCT -3’ 194
Reverse 5’- TGGGCTACAGGCTTGTCACTCG -3’
doi:10.1371/journal.pone.0076039.t001
Figure 1. HMGB1 expression and localization in the human
preadipocyte cell line SW872. A) Expression of HMGB1 by RT-PCR
from total RNA obtained from SW872 cell after 12h of culture, with (+)
and without (2) Reverse Transcriptase (RT). B) Detection of HMGB1
protein in different cell fraction by Western blot analysis. b-actin is a
cytoplasmic protein (Cy) and lamin B a nuclear protein (Nu). C)
Immunofluorescence of HMGB1 in SW872 cells (X 200). Cells were
incubated with mouse anti-HMGB1 primary antibody (1:200), Alexa
Fluor 594 linked secondary antibody (1:1000) and DAPI. Scale bar
indicated 50 mm.
doi:10.1371/journal.pone.0076039.g001
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and associated-signaling pathways could be used as targets for the
development of new therapeutics against pathologies related to
adipose tissue inflammation, insulin resistance and diabetes.
Materials and Methods
Drugs and reagents
Except when indicated, all drugs and reagents were from Sigma
Aldrich (Sigma-Aldrich, France).
Production of recombinant HMGB1 (rHMGB1)
The full length version of human HMGB1 (clone image
5268698, accession number BC066889) was modified by directed
mutagenesis to remove the endogenous NdeI restriction site using
59-AGGCAAAATGTCATCTTATGCATTTTTTGTG-39 and
59-CACAAAAAATGCATAAGATGACATTTTGCCT-39. It
was then amplified by PCR using primers 59-AACCATGGG-
CAAAGGAGATCCTAA-39 and 59-
TTTGAATTCTTGCTGCCGCGCGGCACCAGTTCAT-
CATCATCATCTTCTT-39 and subsequently cloned in pET28
vector using NcoI and EcoRI sites. This lead to a sequence
encoding HMGB1 – thrombin site – C-terminal his-tag. After
transformation of BL21-codon plus E. Coli bacteria (Agilent),
culture and induction were done as described [23]. Cells were
harvested at 3,000 g for 15 min at 4uC. All subsequent steps were
done at 4uC. The pellet was resuspended in 10 mL of
25 mmol.L21 Hepes (PAN Biotech, Germany). Cells were lyzed
by sonification (Misonix ultrasonic liquid processor, France) at
80% of amplitude for 2 min with 10 sec of burst and 10 sec of
pause in the ice. Lysate was centrifuged at 15,000 g for 10 min at
4uC, the supernatant was submitted to the action of DNAse I at
80 U/mL for 30 min at 25uC, then diluted to a final volume of
10 mL and mixed gently with 0.5 mL of agarose Ni-NTA
(Qiagen, France). After 30 min, the column was washed with
10 mL of 25 mmol.L21 Hepes, 500 mmol.L21 NaCl, then with
10 mL of 25 mmol.L21 Hepes, 20 mmol.L21 imidazole, then
with 25 mL of 25 mmol.L21 Hepes, 0.1% (v/v) Triton X-114,
20 mmol.L21 imidazole, then a final washing step with 10 mL of
25 mmol.L21 Hepes, 20 mmol.L21 Imidazole. HMGB1-His was
eluted with 5 mL of 300 mmol.L21 imidazole in 25 mmol.L21
Hepes. The elute (1 mL) was dialyzed overnight at 4uC against
25 mmol.L21 Hepes. Levels of LPS and DNA in the preparation
were evaluated respectively by LAL assay (HyCult Biotechnology,
Uden, The Netherlands) and ethidium bromide (EtBr) coloration
of DNA after gel electrophoresis. Level of LPS was under 1ng.L21
and no DNA was detected by EtBr coloration. Biochemical
evaluation of rHMGB1 was conducted by SDS-PAGE with
coomassie-blue staining and western blot (Figure S4A).
Cell culture and treatment
SW872 liposarcoma cells line (ATCC, HTB-92) were cultured
at 37uC with 5% CO2 in DMEM medium, supplemented with
10% heat inactivated fetal bovine serum and 2 mmol.L21 L-
Glutamine, 1 mmol.L21 sodium pyruvate, 100 U.mL21 of pen-
icillin, 0.1 mg.mL21 of streptomycin and 0.5 mg.mL21 of fungi-
zone (PAN Biotech, Germany). All experiments were done
between passage 2 and 8 at 80% of confluence. For treatment,
the media was replaced by fresh complete media (see above)
containing drugs or rHMGB1 for 5 h or indicated time. Cells were
harvested and kept as frozen pellet for further protein or mRNA
Figure 2. Secreted HMGB1 levels correlate with IL-6 secretion in SW872 cells. A) Expression of IL-6 by RT-PCR from total RNA obtained from
SW872 cell after 12 h in culture, with (+) and without (2) Reverse Transcriptase (RT). B) IL-6 secretion by ELISA assay from SW872 supernatant culture
6h after media renewal (expressed in mean 6 SD) (n = 3). D) Correlation between IL-6 secretion and HMGB1 release in SW872 cell culture media after
renewal of media (n = 3). Pearson’s correlation coefficient (r = 0.9108, p = 0.0116) and Spearman’s rank correlation coefficient (r = 0.9429, p = 0.0167).
All values are expressed as means +/2 SD.
doi:10.1371/journal.pone.0076039.g002
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analysis. The media were centrifuged for 5 min at 800 g and
supernatants were kept at 220uC until use for quantification by
ELISA or Dot-Blot.
RNA interference and retroviral gene transfert
29mer shRNA constructs (TR316576) in retroviral untagged
pRS vector, against HMGB1 were purchased from Origene
(Clinsciences, France). Retroviral particule were produced in PT-
67 packaging cell lines as described by manufacturer’s instructions
(Clontech, Ozyme, France). SW872 were stably infected using the
tissue cell supernantant of transfected PT67 cells as before using
puromycin (1 mg.mL21) as selection agent for twenty days [24].
Blocking antibody assay
SW872 cells were treated with rHMGB1 (1 mg.mL21) and
incubated with control or blocking antibodies for 5 h at 1:20
dilution. Blocking antibodies against TLR2 (clone T2.5,
5 mg.mL21) and TLR4 (clone HTA125, 5 mg.mL21) [25,26] were
purchased from HyCult Biotechnology (Uden, The Netherlands).
Blocking polyclonal antibody against RAGE used at 1:20 dilution
(goat anti-RAGE, AB5484) was purchased from Chemicon
International Inc (Temecula, CA, USA). Blocking rabbit mono-
clonal anti-HMGB1 used at 1:20 dilution (clone D3E5, 6893) was
obtained from Cell Signaling Technology (Ozyme, Saint Quentin,
France). Blocking activity of antibody against RAGE and HMGB1
Figure 3. Secreted HMGB1 controls IL-6 production in SW872 cells. IL-6 levels were determined by ELISA from SW872 cells A) treated with
increasing concentrations of recombinant HMGB1 for 5 h (n = 4) or B) treated or not with rHMGB1 with a dose of 1 mg.mL21 for 5 h in presence of
either an irrelevant control rabbit IgG (CTL) or a rabbit monoclonal anti-HMGB1 (abHMGB1) (n = 4). Detection of IL-6 secretion in SW872 cells treated
for 5 h with C) ethyl-pyruvate (n = 3) or D) glycyrrhizin (n = 3). All values are expressed as means +/2 SD. Degrees of significance are indicated in the
figure captions as follow, * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0076039.g003
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for cytokine activity of HMGB1, were validated in RAW-BLUE
cells using rHMGB1 at 1 mg.mL21 (Invivogen, France).
Lysate preparation and Western Blot analysis
SW872 cells were harvested after two washes with PBS and
pelleted at 800 g for 5 min at 4uC. The pellets were processed for
subcellular fractionation using the NE-PER according to manu-
facturer’s instruction (Thermo Scientific, France). Protein extracts
(cytoplasmic or nuclear fractions) were separated by SDS-PAGE
and transferred to nitrocellulose membranes (Hybond-C extra, GE
Healthcare, France). The Western blot was performed as
described [27]. Monoclonal anti-HMGB1 (clone 2F6 Sigma),
monoclonal anti-b-actin (clone C4, Santa Cruz Biotechnology),
monoclonal anti-lamin B (Oncogene, Cambridge, MA, USA) were
used as primary antibodies at 1:1000 dilution. Anti-rabbit
immunoglobulin-horseradish peroxidase or anti-mouse immuno-
globulin-horseradish peroxidase conjugates (Vector, France) were
used as secondary antibodies and diluted at 1:2000. All antibodies
were diluted in TRIS buffer with 0.1% Tween and 5% (w/v) low
fat milk. Blots were revealed with ECL detection reagents (GE
Healthcare).
ELISA quantification and Dot-Blot analysis
Secretion of cytokines (IL-6, TNF-a) was measured by ELISA
kit (eBiosciences, Austria) according to manufacturer’s instruc-
tions. Of note, no exogenous HMGB1, LPS and IL-6 were
detected in commercial cell culture media or complete media by
Dot-blot, LAL-assay and ELISA, respectively (data not shown).
Secretion of HMGB1 was measured by ELISA kit from IBL
international according to manufacturer’s instructions (IBL,
Germany). 100 mL of SW872 cell culture supernatant were
spotted on nitrocellulose membrane (Hybon-C extra, GE
Healthcare, France) with a Dot-blot apparatus (Biorad). Mem-
branes were processed as for the Western-blot technique.
RNA isolation and RT-PCR
Total RNA was extracted with TRIzol reagent (Invitrogen,
Carlsbad, USA) according to the manufacturer’s specifications.
The reverse transcription (RT) was done with 2 mg of total
extracted RNA and 14.5 mL of RT mix containing: 6 mL of 5X
RT buffer (Invitrogen), 1.5 mL of 0.1 mol.L21 DTT (Invitrogen),
3 mL of 10 mmol.L21 dNTP mix (Promega, Madison), 2.5 mL of
5 U.mL21 of random hexamers (pdN6), 1.5 mL of 40 U.mL21
RNAse Inhibitor (Promega). After a denaturation at 65uC for 5
min, 2 mL of RTase 200 U.mL21 (Invitrogen) were distributed.
The RT steps are the followings, 37uC for 1 h, 95uC for 5 min.
cDNAs were then kept at 4uC. The PCR was done in a final
volume of 20 mL containing 4 mL of 5X PCR buffer (Promega),
2 mL of 25 mmol.L21 MgCl2 (Promega), 0.4 mL of 10 mmol.L
21
dNTP mix, 0.1 mL of 5U.mL21 Taq polymerase (Promega),
11.5 mL of water DNase RNase free, 1 mL of cDNA and 1 mL of
10 mmol.L21 primer mix (Table 1). 30 cycles of PCR were done
with a pre-denaturation at 95uC for 2 min, 30 cycles of PCR
(denaturation at 95uC for 30 sec, annealing at 60uC for 30 sec,
extension at 72uC for 45 sec). Final extension was carried out at
72uC for 5 min, and samples were then kept at 4uC. The size of
PCR products was checked on 1.2% agarose gel electrophoresis
and visualized with EtBr. GAPDH was used as a housekeeping
gene.
Immunofluorescence
SW872 cells were grown on glass coverslips, washed twice with
PBS and then fixed for 5 min in fixation buffer (5% formaldehyde
v/v and 5% glutaraldehyde v/v in PBS) and washed twice with
PBS. Coverslips were conserved at 220uC. Cells were incubated
in the following primary antibody, anti-HMGB1 (Clone 2F6,
Sigma) 1:200 dilution (2.5 mg.mL21) in PBS-BSA 1% (w/v) and
incubated with the secondary antibody Alexa Fluor 594-
conjugated anti-mouse IgG (1:1000 dilution). Nuclei were stained
with DAPI (Sigma, D9542) at a final concentration of
0.1 ng.mL21). Coverslips were mounted in Vectashield (Vector
Labs, Clinisciences, France), and fluorescence was observed using
a Nikon Eclipse E2000-U microscope (Nikon, Tokyo, Japan).
Images were obtained using the Nikon Digital sight PS-U1 camera
system and the imaging software NIS-Element AR (Nikon, Tokyo,
Japan).
Flow cytometry
Cells were harvested after two washes with PBS, then pelleted at
800 g for 5 min. Cells were incubated with 5% (w/v) BSA in PBS
for 10 min at room temperature under agitation. Primary and
secondary antibodies were diluted in PBS-BSA and incubated at
room temperature with agitation for 45 min. Primary antibodies
were anti-TLR2 (clone T2.5, 25 mg.mL21, HyCult Biotechnolo-
gy), anti-TLR4 directly conjugated with R-Phycoerythrin (clone
Figure 4. HMGB1 shRNA dowregulates IL6 secretion. HMGB1
mRNA expression or protein expression were assessed respectively by
RT-PCR (A) or Western blot (B) after 12h in culture of stably SW872
infected with scrumble shRNA (Sh CTL) or HMGB1 shRNA (sh HMGB1)
constructs. C) Detection of IL-6 secretion in stably SW872 infected cells
with scramble shRNA (Sh CTL) or HMGB1 shRNA (sh HMGB1) constructs
after 5h of media renewal (n = 3). All values are expressed as means +/2
SD. Degrees of significance are indicated in the figure captions as follow
*** p,0.001.
doi:10.1371/journal.pone.0076039.g004
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HTA125, 25 mg.mL21 HyCult Biotechnology) or anti-RAGE
(polyclonal antibody, Chemicon international) at 1:100 dilution.
When required, we used anti-goat or anti-mouse conjugated to R-
Phycoerythrin (polyclonal antibody, Southern Biotech) at 1:500
dilution as secondary antibodies. After two washes with PBS, cells
were harvested in PBS. For each experiment 10000 cells were
counted and were analyzed by flow cytometry (Beckman Coulter
FC-500-MPL Flow Cytometer, MXP acquisition software and
CXP analysis software, version 2.2).
Statistical analysis
All values are expressed as mean +/2 SD and are represen-
tative at least of 3 independent experiments. Comparisons between
different treatments have been analyzed by a one-way ANOVA
test. Values of p,0.05 were considered statistically significant for a
Figure 5. HMGB1 mediates IL-6 release through RAGE. A) TLR2, TLR4, RAGE and HMGB1 mRNA expression was assessed by RT-PCR from total
RNA obtained from SW872 cell after 12h in culture, with (+) and without (2) Reverse Transcriptase (RT). B) Cell surface expression of TLR2, TLR4 and
RAGE were analyzed by FACS C) SW872 cells were treated with rHMGB1 1 mg.mL21 for 5 h with control mouse IgG (CTL), TLR2 or TLR4 blocking
antibody (n = 4). D) SW872 cells were treated as in (C) except that control goat IgG (CTL) or goat polyclonal anti-RAGE were used (n = 4). All values are
expressed as means +/2 SD and degrees of significance are indicated in the figure captions as follow, * p,0.05, ** p,0.01, *** p,0.001 and ns = not
significant.
doi:10.1371/journal.pone.0076039.g005
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post-hoc Tukey-Kramer test in order to compare treated versus
non-treated. All statistical tests were done using the software
Graph-Pad Prism version 5.01 (San Diego, CA, USA). Degrees of
significance are indicated in the figure captions as follow:
* p,0.05; ** p,0.01; *** p,0.001, ns = not significant.
Results
1. SW872 as a preadipocyte model
In this study we wanted to test the secretion of HMGB1 and the
contribution to fat inflammation of preadipocyte. We used the
human liposarcoma cell line SW872 as a model. We first tested the
phenotype of SW872 considered as a preadipocyte model. Using
RT-PCR we found expression of preadipocyte markers Pref1,
GATA2 and AEBP in SW872 as in 3T3L1 preadipocyte (Table
S1, Figure S1). We were not able to detect adipocyte markers
FABP4, C/EBPa, PPARc, KLF15, transcripts and the presence of
lipids droplets by Oil Red O staining at any time of our
experimental settings (data not shown). All of these observations
argue in favor of preadipocyte status for SW872 cell line.
2. HMGB1 localization in the human preadipocyte cell
line SW872
We analyzed the basal expression of HMGB1 in the human
preadipocyte SW872 cells by RT-PCR. The transcript of HMGB1
was detected in SW872 cells in basal culture conditions (Figure
1A). We next investigated the cellular localization of HMGB1 in
SW872 cells by immunofluorescence. We found that 100% of
SW872 cells expressed HMGB1 and with an immunostaining
mainly localized to the cytoplasm (Figure 1B). To confirm that
SW872 cells predominantly expressed cytoplasmic HMGB1, we
performed Western blot of cellular fractions of cytoplasm (Cy) and
Figure 6. HMGB1 controls MCP1 (CCL2) secretion. A) MCP1 and TNFa mRNA expression were assessed by RT-PCR from total RNA obtained
from SW872 cell after 12h in culture, with (+) and without (2) Reverse Transcriptase (RT). B) MCP1 and TNFa secretion by ELISA assay from SW872
supernatant culture 6h after media renewal (n = 6). C) IL-6 levels were determined by ELISA from SW872 cells treated with increasing concentrations
of recombinant HMGB1 for 5 h (n = 3). D) Detection of MCP1 secretion in stably infected SW872 with scramble shRNA (Sh CTL) or HMGB1 shRNA (Sh
HMGB1) constructs after 5h of media renewal (n = 3). All values are expressed as means +/2 SD and degrees of significance are indicated in the figure
captions as follow, * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0076039.g006
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nucleus (Nu). The proteins b-actin and lamin B were used as
internal controls to assess the enrichment for cytoplasmic and
nuclear proteins, respectively. High levels of cytoplasmic and low
amount of nuclear HMGB1 were detected in SW872 cells
confirming the immunofluorescence data (Figure 1C). These
results suggest that HMGB1 accumulates in the cytoplasm of the
human preadipocyte cell line SW872. The same results were
observed using the mouse 3T3L1 preadipocyte cell line (Figure
S2).
3. Secreted HMGB1 level correlates with IL-6 secretion in
SW872 cells
It was previously shown that high levels of HMGB1 in the
cytoplasm were typically associated with its active secretion [28].
We first tested the release of HMGB1 by SW872 cells by Dot blot
from tissue cell supernatant (TCS). HMGB1 was released as soon
as 30 min after media renewal and the level of secreted HMGB1
increased continuously (Figure S3A). We did not observe SW872
cell necrosis during this experiment as addressed by the LDH
assay (Figure S3B). Hence, HMGB1 secretion was not due to
passive release. All these observations also occurred in 3T3L1
preadipocyte cell lines (Figure S3C). We next used RT-PCR and
ELISA to show that IL-6 is expressed (Figure 2A) and released
(1093.63 pg.mL21 624.57) by SW872 cells in normal cell culture
conditions (Figure 2B).
In order to investigate a potential correlation between HMGB1
and IL-6 secretion in SW872 cells we evaluated the release of IL-6
and HMGB1 by ELISA after media renewal. We further
demonstrated a significant positive relationship between secreted
HMGB1 levels and IL-6 release (Spearman’s rank correlation
coefficient: r = 0.9429 and p,0.05; Pearson’s correlation coeffi-
cient: r = 0.9108 and p,0.05) (Figure 2C). These results suggest
that the expression and release of IL6 correlated with the release of
HMGB1 by SW872 cells as in 3T3L1 (Figure S3C).
4. Secreted HMGB1 controls the release of IL-6 in SW872
cells
We produced a recombinant form of human HMGB1
(rHMGB1) to investigate the direct effects of HMGB1 on
SW872 adipocytes (Figure S4A). SW872 cells were stimulated
with increasing concentrations of rHMGB1 and levels of secreted
IL-6 were quantified by ELISA. Whereas the secretion of IL-6 was
not significantly affected after treatment of SW872 cells with 100
ng.mL21 of rHMGB1, higher concentrations of rHMGB1
significantly enhanced the release of IL-6 (p,0.01) and in a dose
dependent manner (Figure 3A). IL-6 secretion was not related to
rHMGB1 cytotoxicity as cell viability was not affected by all tested
dose of rHMGB1 (Figure S4B). Moreover, HMGB1 blocking
antibody (abHMGB1) induced a significant reduction of IL-6
secretion in SW872 cells stimulated or not stimulated with
rHMGB1 (Figure 3B). These results suggest that IL-6 secretion
can be regulated by extracellular HMGB1.
To further test the contribution of HMGB1 release to IL-6
secretion, cells were treated with two HMGB1 inhibitors, ethyl-
Figure 7. Central role of HMGB1 adipokine in LGI of fat tissue. Model depicting the novel role of HMGB1 as an adipokine involved in fat tissue
inflammation, obesity and associated-chronic disorders such as diabetes type II. We found that HMGB1 is secreted and interacts via an autocrine and/
or paracrine manner with RAGE on preadipocytes. This could contribute to low grade inflammation (LGI) of the fat tissue with the elevated expression
of major pro-inflammatory cytokines such as IL-6 and MCP1. We could further hypothesize that HMGB1 released by preadipocytes can attract, via
MCP1, macrophages and leading to activation through TLR2, TLR4 and RAGE. Finally, the pool of proinflammatory factors and recruited immune cells
could instigate the LGI and the insulin resistance in liver and muscle cells.
doi:10.1371/journal.pone.0076039.g007
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pyruvate that blocks the release of HMGB1 (Figure S4C) [29] and
glycyrrhizin that interacts with HMGB1 and prevents its binding
to its cellular receptors (e.g. TLR2, TLR4, RAGE) [30,31]. The
drug concentrations used herein did not affect cell viability as
measured by MTT assay for SW872 (data not shown). The
secretion of IL-6 was significantly decreased by 75% (p,0.001)
after treatment of SW872 cells with low concentrations of ethyl-
pyruvate and in a dose independent manner (319.52 pg.mL21 of
IL-6 secretion 6 73.88 after treatment with 10 mmol.L21 of Ethyl-
pyruvate, 323.99 pg.mL21 688.64 after treatment with
20 mmol.L21 281.54 pg.mL216237.78 after treatment with
30 mmol.L21) compared to untreated cells (1220 pg.mL21688.68)
(Figure 3C). Similarly, the release of IL-6 significantly decreased
by 55% (p,0.05) after treatment of SW872 cells with
500 ng.mL21 (615.79 pg.mL21 of IL-6 secretion 6 257.01 or
1000 ng.mL21of glycyrrhizin (574.95 pg.mL216196.24) com-
pared to untreated cells (1300 pg.mL216202.32) (Figure 3D).
To validate our observations we used an shRNA which target
human HMGB1 mRNA and efficiently down regulated HMGB1
at mRNA, protein level and in the media (Figure 4A, B and C).
HMGB1 down regulation was accompanied by at least 50%
reduction (p,0.001) of the release of IL-6 (Figure 4C).
5. HMGB1-mediated IL-6 secretion involves the receptor
RAGE in SW872 cells
It is well documented that HMGB1 can bind to the cellular
receptors TLR2, TLR4 and RAGE [20]. Hence, we first tested the
expression of these receptors in SW872 cells using RT-PCR and
FACS analysis. TLR2, TLR4 and RAGE mRNAs were detected
in SW872 cells (Figure 5A) and all three receptors were detected at
the cell surface by FACS (Fig5B). Next, we investigated whether
HMGB1-mediated secretion of IL-6 was dependent of these cell
surface receptors in SW872 cells using blocking antibodies against
TLR2, TLR4 and RAGE. SW872 cells were treated for 5 h with
rHMGB1 together with either an irrelevant mouse antibody (IgG
control) or blocking antibodies against TLR2, TLR4 or RAGE as
previously described [25]. Whereas TLR2 and TLR4 blocking
antibodies had no significant effects on IL-6 secretion induced by
rHMGB1 (Figure 5C), RAGE blocking antibody significantly
decreased IL-6 secretion by 3 fold (p,0.001) (85.10% of IL-6
secretion 6 12.53%) compared to cells stimulated with rHMGB1
and incubated with irrelevant IgG control (258.89% of IL-6
secretion 6 8.54) (Figure 5D). This result was confirmed using
another antibody against RAGE (rabbit anti-RAGE, 4679S, Cell
Signaling Technology) (data not shown). Our results suggest that
HMGB1-mediated secretion of IL-6 involved the receptor RAGE
expressed by SW872 cells.
6. HMGB1 control MCP1 secretion in SW872
In LGI other inflammatory markers were also important like
TNFa and MCP1 (CCL2). We investigated basal expression of
TNFa and MCP1 in our SW872 preadipocyte model, as
previously observed [22,32] high levels of MCP1 was expressed
and secreted as addressed by RT-PCR and ELISA respectively
(Figure 6 A and B). Low levels of TNFa was detected in basal
conditions. The same pattern was found in 3T3L1 preadipocyte
by RT-PCR (Figure S5). MCP1 secretion was next monitored in
response to treatment of SW872 cells with rHMGB1. rHMGB1
significantly enhanced the release of MCP1 (p,0.01) in a dose
dependent manner (Figure 6C).
To validate HMGB1 action, we analyzed MCP1 secretion after
treatment of SW872 with plasmid encoding shRNA against
HMGB1 as described above for IL6. Down regulation of HMGB1
levels significantly (p,0.01) reduced MCP1 secretion (Figure 6D).
All together these observations argue in favor of MCP1 secretion
controlled by HMGB1 in preadipocyte.
Discussion
The secretion of HMGB1 by macrophages is well characterized
and essentially through the active release from cytoplasmic stores.
Moreover, secreted HMGB1 can induce a signaling cascade
leading to the production and release of a plethora of pro-
inflammatory molecules and leading to LGI. It is recognized that
adipose tissue contributes to LGI but the role of HMGB1
specifically on preadipocytes has remained largely unknown.
To test the hypothesis that HMGB1could participate to LGI in
fat tissues, we used the human liposarcoma cell line SW872 as a
preadipocyte model [33,34,35,36,37,38]. Herein, we showed that
HMGB1 accumulated in the cytoplasm of SW872 and was
secreted in the cell culture supernatants overtime. This observation
is in agreement with a previous study where the authors showed
that highly acetylated form of HMGB1 preferentially accumulated
in the cytoplasm of monocytes before being secreted [28]. It is
generally accepted that a dominant activity of histone acetyl
tranferase activity and/or a lower activity of histone deacetylase
could contribute to the accumulation of cytoplasmic HMGB1 but
this remains to be tested in our cell model.
Interestingly, we found that SW872 cells released constitutively
high levels of IL-6 and through a direct action of the endogenous
HMGB1. The levels of secreted IL6 correlated positively with the
level of HMGB1 and, more importantly, we found that two
inhibitors of HMGB1 release impaired IL6 production by SW872.
Thus, our data show strong inhibitory activities either with ethyl-
pyruvate [29] or glycyrrhizin which interacts specifically to A and
B boxes of HMGB1 preventing its binding to its receptors [30].
These two inhibitors interfere with HMGB1 effect on IL-6
secretion. The decrease in IL-6 production mediated by the
inhibition of endogenous HMGB1 might suggest an autocrine and
paracrine activity of HMGB1 to regulate the secretion of IL-6 in
SW872 cells. We observed that IL-6 secretion was less inhibited by
glycyrrhizin than by ethyl-pyruvate. This difference might be due
to the double action of ethyl-pyruvate which interferes with
HMGB1 secretion [29] but also decreases NF-kB DNA binding
activity, thus reducing the production of cytokines [39].
When SW872 cells were exposed to rHMGB1, we observed an
increased secretion of IL-6 in a dose dependent manner further
suggesting that HMGB1 can act in a direct manner on fat cells to
promote the release of IL-6.
In a previous study, IL6 secretion was significantly increased in
culture medium of adipocytes in presence of LPS [40]. Moreover,
LPS was more effective with higher IL-6 secretion in preadipocyte
compared to mature adipocytes [16,17,18]. It is known that
HMGB1 can strongly enhance the cytokine response evoked by
LPS [41,42] and this is to be correlated with the observations that
HMGB1 secretion by preadipocyte was not observed in fully
mature adipocyte [43]. All together these observations would
argue for a more potent inflammatory role of preadipocyte when
compared to mature adipocytes.
The strong association between high levels of secreted HMGB1
by SW872 and strong levels of IL-6 is interesting to shed new light
on the mechanisms of LGI and possible therapeutic avenues. It has
also been shown a strong link between IL-6 serum levels and
insulin resistance [8,15,44,45,46]. Hence, this relation between
IL6 and insulin resistance should be extended to propose a central
role of HMGB1 in insulin resistance through it action on IL6
secretion. The therapeutic potentials of HMGB1 inhibitors should
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now be tested in the context of insulin resistance pathologies and
experiments along these lines are now highly warranted.
Using our preadipocyte SW872 cell model, we showed that
HMGB1 behave as a positive regulator of MCP1 secretion. As
MCP1 act as a chemokine which attract macrophages, HMGB1
may contribute to immune cells infiltration in adipose tissue and
instigating LGI. The presence of macrophages with potent pro-
inflammatory activities and in response to HMGB1 released in the
vicinity of the adipocytes may contribute further to insulin
resistance (Figure7) [47,48,49].
Several key receptors have been implicated in HMGB1
signaling, including RAGE, TLR2 and TLR4. We showed that
RAGE, TLR2 and TLR4 are transcribed and expressed at the
surface of SW872 cells. However, only RAGE blocking antibody
induced a strong inhibition of IL-6 secretion by preadipocytes
SW872 stimulated with rHMGB1.
RAGE is known to be implicated in obesity, diabetes and their
complications [50]. This implication is mostly related to its
capacity to interact with advanced glycation end products (AGE)
[51]. AGE can signal through RAGE to activate oxidative stress
and inflammation and finally interfere with insulin-signaling
pathways in adipocytes to decrease insulin sensitivity [52,53]. It
will be essential to decipher the signaling pathways engaged by
HMGB1 binding to RAGE in fat cells and although the role of
soluble RAGE (natural antagonist) in this paradigm. Moreover, we
will need to address whether AGE and HMGB1 can compete for
the same binding site on RAGE and emphasizing possible
antagonistic effects yet to be identified. We will need to study
the signals downstream of RAGE and perform transcriptomic
profiling of SW872 prior to and after HMGB1 stimulation. We
used herein a model of human preadipocyte cells and it would be
interesting to test the contribution of HMGB1 in primary cultures
of human adipose cells and in vivo following the injection of
HMGB1 in fat tissue sites.
Our results argue in favor of a central effect of RAGE in fat
tissue inflammation. Administration of soluble RAGE or blocking
antibody can induce a protective effect against inflammation and
diabetes [54,55] and this could be due to the interference with
HMGB1 pro-inflammatory functions. Remarkably, little is known
about the distribution of HMGB1 in fat tissues and whether the
level of soluble HMGB1 (in blood and fat tissues) is increased in
response to obesity. Experiments along these lines are now highly
warranted following cohorts of patients and analyzing sera and
tissue biopsies for the presence of soluble HMGB1 and possible
correlations with elevated levels of proinflammatory cytokines and
adipokines.
In summary, our study is the first report ascribing a novel
proinflammatory activity of HMGB1 on adipose tissue and
particularly in preadipocyte. We can consider that soluble
HMGB1 is a novel adipokine secreted by preadipocyte and
controlling inflammation through the binding to RAGE receptors
[56,57]. Indeed, our observations showed a direct involvement of
HMGB1 in controlling the secretion of IL-6 and MCP1 in adipose
tissues (Figure7). Experiments are now highly warranted to
decipher the role of HMGB1/RAGE in LGI and numerous
associated chronic pathologies.
Supporting Information
Figure S1 Preadipocyte markers expression in SW872
and 3T3L1 cell lines. Expression of pref-1, GATA2, AEBP by
RT-PCR from total RNA obtained from SW872 cell after 12 h in
culture (A) or from 3T3L1 after 16h in culture, with (+) and
without (2) Reverse Transcriptase (RT). GAPDH served as
housekeeping gene.
(TIF)
Figure S2 HMGB1 expression and localization in the
human preadipocyte cell line 3T3L1. A) Expression of
HMGB1 by RT-PCR from total RNA obtained from 3T3L1 cell
culture after 16h in culture, with (+) and without (2) Reverse
Transcriptase (RT). B) Detection of HMGB1 protein in different
cell fractions by Western blot analysis. HSP60 is a cytoplasmic
protein (Cy) (Antibody from Sigma-aldrich clone LK2) and H4 a
nuclear protein (Nu) (Antibody from Santa-Cruz Biotechnology sc-
10810).
(TIF)
Figure S3 SW872 and 3T3L1 releases actively HMGB1
in cell culture media. A) Quantification of HMGB1 secretion
after renewal of cell culture media from SW872 cells in time
dependent manner by Dot-Blot analysis. B) LDH assay on cell
culture media from SW872 from A) according to manufacturer
instructions (Sigma-aldrich). C) Quantification of HMGB1 and
IL6 secretion after renewal of cell culture media from 3T3L1 cells
in time dependent manner by respectively by Dot-Blot and ELISA
assays.
(TIF)
Figure S4 HMGB1 inhibition downregulates IL6 re-
lease. A) Biochemical evaluation of HMGB1 purity by SDS-
PAGE followed by Coomassie Blue staining or Western blotting
with HMGB1 antibody (2F6 from Sigma-aldrich). B) Cytotoxicity
evaluation of rHMGB1 on SW872 cell line using MTT assay
according to manufacturer’s instructions (Sigma-aldrich). C)
Impact of ethylpyruvate on HMGB1 secretion by Dot-Blot
analysis.
(TIF)
Figure S5 MCP1 (CCL2) and TNFa mRNA expression.
MCP1 and TNFa mRNA expression were assessed by RT-PCR
from total RNA obtained from 3T3L1 cells after 12h of culture,
with (+) and without (2) Reverse Transcriptase (RT).
(TIF)
Table S1 List of primers used in this study for RT-PCR
on 3T3L1 and SW872 RNA.
(TIF)
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